Tracking changes in the vraSR and graSR two component regulatory systems during the development and loss of vancomycin non-susceptibility in a clinical isolate

Clinical Microbiology and Infection

Volumn 17, Issue 8, 2011, Pages 1268-1272

  Doddangoudar, V C ^a   Boost, M V ^a   Tsang, D N C ^b   O'Donoghue, M M ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Methicillin resistant Staphylococcus aureus; Treatment failure; Two component regulatory systems; Vancomycin; Vancomycin intermediately susceptible

Indexed keywords

BACTERIAL PROTEIN; DAPTOMYCIN; GRASR PROTEIN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN; VRASR PROTEIN;

AGAR DILUTION; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BLOOD CULTURE; CASE REPORT; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 79960671348     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03463.x     Document Type: Article

References (20)

1. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. M100-S20. Wayne, PA: CLSI, 2010.
3. EUCAST. Available at: (last accessed 6 December 2010). Glycopeptides - EUCAST clinical MIC breakpoints 2009-09-29.
4. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two compartment system vraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 2003; 49: 807-821.
5. Neoh H, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 2008; 52: 45-53.
6. Cui L, Neoh HM, Shoji M, Hiramatsu K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 1231-1234.
7. Gardete S, Wu SW, Gill S, Tomasz A. Role of vraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 3424-3434.
8. Doddangoudar VC, O'Donoghue MM, Boost MV, Tsang DN, Appelbaum PC. Rapid detection of vancomycin non-susceptible Staphylococcus aureus using the spiral gradient endpoint technique. J Antimicrob Chemother 2010; 65: 1959-1963.
9. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988; 16: 10881-10890.
10. Bannerman TL, Hancock GA, Tenover FC, Miller JM. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol 1995; 33: 551-555.
11. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 1008-1105.
12. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterisation of vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008; 57: 72-79.
13. Moreira B, Boyle-Vavra S, deJonge BL, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1788-1793.
14. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 2002; 50: 383-391.
15. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
16. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42: 1652-1653.
17. Adhikari RP, Scales GC, Kobayashi K, Smith JM, Berger-Bächi B, Cook GM. Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus. J Antimicrob Chemother 2004; 54: 360-363.
18. Kato Y, Suzuki T, Ida T, Maebashi K. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. J Antimicrob Chemother 2010; 65: 37-45.
19. Mwangi MM, Wu SW, Zhou Y et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 29: 9451-9456.
20. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin intermediate and heterogeneous vancomycin intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.